New antipsychotic medications: What advantages do they offer?

Postgraduate Medicine

Volumn 101, Issue 2, 1997, Pages 207-214

  Citrome, Leslie ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE;

AGRANULOCYTOSIS; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NAUSEA; NOSE CONGESTION; PATIENT COMPLIANCE; REVIEW; SCHIZOPHRENIA; TACHYCARDIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG COSTS; HUMANS; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; UNITED STATES;

EID: 1842298169     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.1997.02.166     Document Type: Article

References (20)

1. Citrome L. Differential diagnosis of psychosis: a brief guide for the primary care physician. Postgrad Med 1989; 85 (4): 273 – 80
2. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988; 45: 789 – 96
3. Alvir JMJ, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329 (3): 162 – 7
4. Clozaril (clozapine). Patient management handbook. East Hanover, NJ: Sandoz Pharmaceuticals Corp, 1995
5. Kronig MH, Munne RA, Szymanski S, et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 1995; 152 (2): 179 – 82
6. McEvoy JP. Dosing issues: target symptoms and dose response. Psych Ann 1995; 25 (5): 297 – 300
7. Meltzer HY. Clozapine. Is another view valid? (Editorial) Am J Psychiatry 1995; 152 (6): 821 – 5
8. Carpenter WT, Conley RR, Buchanan RW, et al. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995; 152 (6): 827 – 32
9. Friedman LJ, Tabb SE, Worthington JJ, et al. Clozapine—a novel antipsychotic agent. (Letter) N Engl J Med 1991; 325: 518
10. Klimke A, Klieser E. Sudden death after intravenous application of lorazepam in a patient treated with clozapine. (Letter) Am J Psychiatry 1994; 151 (5): 780
11. Cobb CD, Anderson CB, Seidel DR. Possible interaction between clozapine and lorazepam. (Letter) Am J Psychiatry 1991; 148 (11): 1606 – 7
12. Clozaril product information. In: Physicians' Desk Reference. 50th ed. Mont-vale, NJ: Medical Economics Co, 1996, pp 2252 – 55
13. Centorrino F, Baldessarini RJ, Frankenburg FR, et al. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996; 153 (6): 820 – 22
14. Marder SR, Melbach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151 (6): 825 – 35
15. Jibson MD, Tandon R. Special report: a summary of research findings on the new antipsychotic drugs. Directions Psychiatry 1996; 16 (May): 1 – 8
16. Ereshefsky L, Mack RJ, Morris DD, et al. The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients. (Abstr) Psychopharmacology Bull 1996; 32 (3): 441
17. Tollefson G, Beasley C, Tran P, et al. Olanzapine versus haloperidol: acute results of the multi-center international trial. (Abstr) Psychopharmacology Bull 1996; 32 (3): 401
18. Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: results from a multiple fixed-dose, placebo-controlled trial. (Abstr) Psychopharmacology Bull 1996; 32 (3): 391
19. Hong WW, Arvanitis LA, Miller BG, et al. The atypical profile of ICI 204,636 is supported by its lack of induction of extrapyramidal symptoms. (Abstr) Psychopharmacology Bull 1996; 32 (3): 458
20. Harrigan EP, Reeves K. The efficacy and safety of two fixed doses of ziprasidone in schizophrenia. (Abstr) Psychopharmacology Bull 1996; 32 (3): 456